Angiodynamics Inc (ANGO) · Nov 18, 2026 · Other events
1M-share plan increase — Equity reserve increased from 9.05M to 10.05M shares
AngioDynamics’ shareholder vote approved a 1 million-share equity-plan increase, preserving hiring and retention flexibility while raising potential dilution.
AngioDynamics is in the middle of a Med Tech-led growth transition. Its Auryon, thrombectomy and NanoKnife platforms drove 18.4% Med Tech growth in fiscal 2026, while the company reported an eighth consecutive quarter of double-digit Med Tech growth in fiscal Q1 2027.
The filing confirms shareholder approval of more equity-compensation capacity, not an immediate share issuance. Shareholders approved the amended 2020 Plan, which increases the authorized reserve from 9.05 million to 10.05 million shares; the proxy had already disclosed that proposal and its terms. The filing states that shareholders voted to approve the plan “to increase the number of shares available for issuance.” 〔0〕
The business effect is flexibility, with a larger potential dilution overhang. The additional 1 million shares give AngioDynamics room to continue using stock-based awards as it builds its higher-growth platforms and competes for talent, but the approval itself does not grant those shares or change current ownership. The proxy estimated that issuing all outstanding and newly available awards could lift potential fully diluted dilution from approximately 15.5% to 17.2%.
The rest of the meeting was routine governance confirmation. Both director nominees were elected, Deloitte was ratified, and executive compensation received advisory approval. The filing reports that the amended plan proposal “was approved based upon the following votes.” 〔1〕
Bottom line: This preserves an expected tool for AngioDynamics’ growth strategy but adds future dilution capacity. Because the proposal and its terms were disclosed before the vote, the filing confirms rather than changes the company’s operating story.
Future equity awards under the amended 2020 Plan
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!